Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Identification of a tumor-derived p53 mutant with novel transactivating selectivity

Abstract

MDM2 is a p53-responsive molecule that when overexpressed, can alter growth control pathways via p53-dependent and independent mechanisms. We have identified a mutant p53 containing line that expresses high levels of transcripts that are regulated by the p53-responsive promoter of the MDM2 gene. Analysis of cloned product obtained from these tumor cells revealed that they harbor a mutant p53 protein (possessing an Arg to Gln substitution at codon 213) that is a potent transactivator of MDM2 expression. Consistent with this activity, the R213Q mutant was found to have the ability to interact with DNA sequences located within the MDM2 promoter. In contrast to previously described tumor-derived p53 mutants which retain MDM2 transactivation function and possess partial growth suppressive activity, the R213Q mutant is severely compromised in its ability to induce p53-regulated transcripts that encode for proteins involved in cell-cycle arrest and apoptosis. The R213Q mutant can also be expressed at high levels in stably transfected cells and cells that harbor this mutant possess elevated levels of MDM2 protein. The R213Q mutant was also found to be able to up-regulate MDM2 during a genotoxic stress response. R213Q is the first described tumor-derived p53 mutant that is deficient at up-regulating both cell cycle arrest and apoptotic factors, but is highly proficient at inducing the growth-promoting molecule MDM2.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B. . 1990 Science 249: 912–915.

  • Barak Y, Juven T, Haffner R and Oren M. . 1993 EMBO J. 12: 461–468.

  • Boyd KE, Wells J, Gutman J, Bartley SM and Farnham PJ. . 1998 Proc. Natl. Acad. Sci. USA 95: 13887–13892.

  • Bull EK, Chakrabarty S, Brodsky I and Haines DS. . 1998 Oncogene 16: 2249–2257.

  • Cho Y, Gorina S, Jeffrey PD and Pavletich NP. . 1994 Science 265: 346–355.

  • Crook T, Marston NJ, Sara EA and Vousden KH. . 1994 Cell 79: 817–827.

  • Dubs-Poterszman MC, Tocque B and Wasylyk B. . 1995 Oncogene 11: 2445–2449.

  • Duthu A, Debuire B, Romano J, Ehrhart JC, Fiscella M, May E, Appella E and May P. . 1992 Oncogene 7: 2161–2167.

  • Eischen CM, Weber JD, Roussel MF, Sherr CJ and Cleveland JL. . 1999 Genes Dev. 13: 2658–2669.

  • el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B. . 1992 Nature Genet. 1: 45–49.

  • el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.

  • Fakharzadeh SS, Trusko SP and George DL. . 1991 EMBO J. 10: 1565–1569.

  • Frazier MW, He X, Wang J, Gu X, Cleveland JL and Zambetti GP. . 1998 Mol. Cell. Biol. 18: 3735–3743.

  • Friedlander P, Haupt Y, Prives C and Oren M. . 1996 Mol. Cell. Biol. 16: 4961–4971.

  • Funk WD, Pak DT, Karas RH, Wright WE and Shay JW. . 1992 Mol. Cell. Biol. 12: 2866–2871.

  • Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC and Montesano R. . 1998 Nucleic Acids Res. 26: 205–213.

  • Haines DS, Landers JE, Engle LJ and George DL. . 1994 Mol. Cell. Biol. 14: 1171–1178.

  • Johnson P, Gray D, Mowat M and Benchimol S. . 1991 Mol. Cell. Biol. 11: 1–11.

  • Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B. . 1992 Science 256: 827–830.

  • Jones SN, Roe AE, Donehower LA and Bradley A. . 1995 Nature 378: 206–208.

  • Jones SN, Hancock AR, Vogel H, Donehower LA and Bradley A. . 1998 Proc. Natl. Acad. Sci. USA 95: 15608–15612.

  • Lin J, Teresky AK and Levine AJ. . 1995 Oncogene 10: 2387–2390.

  • Ludwig RL, Bates S and Vousden KH. . 1996 Mol Cell. Biol. 16: 4952–4960.

  • Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP and Finlay CA. . 1997 Genes Dev. 11: 714–725.

  • Marks DI, Vonderheid EC, Kurz BW, Bigler RD, Sinha K, Morgan DA, Sukman A, Nowell PC and Haines DS. . 1996 Br. J. Hemat. 92: 890–899.

  • Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB and Kouzarides T. . 1995 Nature 375: 691–694.

  • Montagnoli A, Guardavaccaro D, Starace G and Tirone F. . 1996 Cell Growth Differ. 7: 1327–1336.

  • Montes de Oca Luna R, Wagner DS and Lozano G. . 1995 Nature 378: 203–206.

  • Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL. . 1999 Genes Dev. 13: 2490–3501.

  • Pan Y and Haines DS. . 1999 Cancer Res. 59: 2064–2067.

  • Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B. . 1997 Nature 389: 300–305.

  • Roemer K. . 1999 Biol. Chem. 380: 879–887.

  • Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C and Puisieux A. . 1996 Nature Genet. 14: 482–486.

  • Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M and Vousden KH. . 1996 EMBO J. 15: 827–838.

  • Sigalas I, Calver AH, Anderson JJ, Neal DE and Lunec J. . 1996 Nature Med. 2: 912–917.

  • Sun P, Dong P, Dai K, Hannon GJ and Beach D. . 1998 Science 282: 2270–2272.

  • Waldman T, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 5187–5190.

  • Wang Y, Schwedes JF, Parks D, Mann K and Tegtmeyer P. . 1995 Mol. Cell. Biol. 15: 2157–2165.

  • Wu X, Bayle JH, Olson D and Levine AJ. . 1993 Genes Dev. 7: 1126–1132.

  • Xiao G, White D and Bargonetti J. . 1998 Oncogene 16: 1171–1181.

  • Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR and Livingston DM. . 1995 Nature 375: 694–698.

  • Yang X, Pater A and Tang SC. . 1999 Oncogene 18: 4546–4553.

  • Zambetti GP, Bargonetti J, Walker K, Prives C and Levine AJ. . 1992 Genes Dev. 6: 1143–1152.

  • Zauberman A, Flusberg D, Haupt Y, Barak Y and Oren M. . 1995 Nucleic Acids Res. 23: 2584–2592.

  • Zhu J, Jiang J, Zhou W and Chen X. . 1998 Cancer Res. 58: 5061–5065.

  • Zhu J, Jiang J, Zhou W, Zhu K and Chen X. . 1999 Oncogene 18: 2149–2155.

Download references

Acknowledgements

The authors would like to thank W el-Deiry for helpful discussions and D George and M Murphy for critically reviewing the manuscript and M Murphy for help with ChIP. This work was supported in part by grants from NIH (CA70165) and the US Army (DAMD17-97-1-7169).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pan, Y., Haines, D. Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 19, 3095–3100 (2000). https://doi.org/10.1038/sj.onc.1203663

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203663

Keywords

This article is cited by

Search

Quick links